REVIEW ARTICLE
Year : 2017 | Volume
: 15 | Issue : 3 | Page : 169--176
Oral antidiabetic agents: Recently available novel oral antidiabetic agents in India: A clinical review
Nitin Kapoor, Nihal Thomas
Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital, Vellore, India; Non communicable Diseases Unit, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
Correspondence Address:
Nitin Kapoor
Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore - 632 004, Tamil Nadu, India
Oral anti-diabetic agents form an important therapeutic strategy in the management of diabetes, after lifestyle modification. There are several new agents available, like dipeptidyl peptidase 4 (DPP4) inhibitors and sodium- glucose cotransporter 2 (SGLT2) inhibitors have been approved for use as monotherapy when diet and exercise are inadequate and when metformin is not tolerated, and can also be utilized as an add on to other glucose-lowering agents, including insulin. The therapeutic, pharmacokinetic and safety profiles of these agents are different from the older agents. Hydroxychloroquine (hcq) and bromocriptine have been recently cleared for use and show beneficial effects in control of blood glucose and HbA1C levels.
How to cite this article:
Kapoor N, Thomas N. Oral antidiabetic agents: Recently available novel oral antidiabetic agents in India: A clinical review.Curr Med Issues 2017;15:169-176
|
How to cite this URL:
Kapoor N, Thomas N. Oral antidiabetic agents: Recently available novel oral antidiabetic agents in India: A clinical review. Curr Med Issues [serial online] 2017 [cited 2023 Mar 30 ];15:169-176
Available from: https://www.cmijournal.org/article.asp?issn=0973-4651;year=2017;volume=15;issue=3;spage=169;epage=176;aulast=Kapoor;type=0 |
|
|
|
